Chordia Therapeutics (190A) · InitiativeRestated
Research and development of small-molecule first-in-class drugs with novel mechanisms of action
First written in FY2024-Q3. 4 of 6 entries say "Restated". Latest entry: 2026-10-15.
6entries
3years
2from disclosures
How it moved
Same theme, other companies
R&D Modality Strategy Centered on Small-Molecule DrugsA theme 5 companies write about · 0 as a headwind · 5 as a tailwind
0 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2026-H1RestatedAnnual report
「In particular, we are focusing on the research and development of innovative small-molecule drugs with unprecedented, novel mechanisms of action, or first-in-class drugs.」
The focus on R&D of small-molecule, first-in-class drugs with novel mechanisms of action has been reaffirmed. - FY2025-H1RestatedAnnual report
「We are researching and developing innovative small-molecule drugs with unprecedented, novel mechanisms of action, or first-in-class drugs.」
The policy of researching and developing small-molecule, first-in-class drugs with novel mechanisms of action has been reiterated. - FY2024RestatedAnnual report
「Since our founding, we have made creating first-in-class anticancer drugs our mission.」
The policy of researching and developing small-molecule, first-in-class anticancer drugs with novel mechanisms of action continues. - FY2024-Q3First statedAnnual report
「We are researching and developing innovative small-molecule drugs with unprecedented, novel mechanisms of action, or first-in-class drugs.」
A core R&D policy is to develop small-molecule drugs with mechanisms of action different from those of existing treatments.